Hipertensi Resisten

Starry H Rampengan

Abstract


Hipertensi resisten merupakan faktor risiko utama dari berbagai penyakit, sehingga terjadi peningkatan kejadian penyakit jantung iskemik, gagal jantung, kejadian serebrovaskular, dan disfungsi ginjal. Hipertensi dikatakan resisten terhadap pengobatan ketika strategi terapi yang mencakup modifikasi gaya hidup yang tepat ditambah penggunaan diuretik dan dua obat antihipertensi lain dari kelas yang berbeda pada dosis yang memadai (tapi tidak harus termasuk antagonis reseptor mineralokortikoid) gagal untuk menurunkan angka tekanan darah ke < 140/90mmHg. Lebih jauh, prevalensi hipertensi yang tidak terkontrol juga meningkat, meskipun terjadi kemajuan dalam farmakoterapi. Pasien dengan pengobatan hipertensi resisten (tekanan darah ? 140/90 mmHg) meskipun telah menggunakan  ? 3 obat antihipertensi, termasuk diuretik, sering memiliki faktor risiko tinggi untuk kejadian penyakit jantung dan akibatnya beresiko lebih tinggi mengalami kerusakan organ serta morbiditas kardiovaskular. Penyebab hipertensi resisten bervariasi seperti hipertensi white-coat, ketidakpatuhan terhadap terapi obat, dan pilihan obat atau dosis yang tidak tepat, maka estimasi proporsi pasien dengan rentang dirawat karena hipertensi 5-16%.

Resistant hypertension  is a major risk factor of numerous diseases, that resulting the increase of incidence of ischemic heart disease, heart failure, cerebrovascular events, and renal dysfunction. Hypertension is defined resistant to the treatment if  therapeutic strategy that includes appropriate lifestyle modification and the using of  diuretic and two antihypertensive drugs from  different classes in adequate doses (without mineralocorticoid receptor antagonist) fails to reduce blood pressure level to  < 140/90mmHg. Furthermore, the prevalence of uncontrolled hypertension is also increase, in spite of advances in pharmacotherapy. The treatment of patients with resistant hypertension (blood pressure ? 140/ 90 mmHg despite ? 3 antihypertensive medications, including a diuretic) often have other risk factors for cardiovascular disease and consequently they have higher risk for end-organ damage and cardiovascular morbidities. The proportion of patients with resistant hypertension ranges from 5 to 16%, when confounding causes, such as white-coat hypertension, non-adherence to drug therapy, and inappropriate drug selection or dosing, are eliminated.

 


Keywords


Hipertensi resisten; Tekanan darah; Manajemen

Full Text:

Download File

References


Burnier M, Schneider MP, Chiolero A, et al. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001;19:335-41.

Calhoun DA, Jones D, Textor S, et al. From the American Heart Association Professional Education Committee of the Council Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement for High Blood Pressure Research. Hypertension 2008;51:1403-1419.

Calhoun DA, Nishizaka MK, Zaman MA, et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest, vol. 125, no. 1, pp. 112-117, 2004.

Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892-6.

Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich) 2007;9 (1 Suppl 1):19-24.

Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52.

Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.

Cora LBT, Michael EE. Resistant Hypertension: Identifying Causes and Optimizing Treatment Regimens. Southern Medical Journal 2008;101:166-73.

Costas T, Athanasios K, Dimitris F, et al. Pathophysiology of Resistant Hypertension: The Role of Sympathetic Nervous System. International Journal of Hypertension Volume 2011, Article ID 642416.

Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001;19:2063-2070.

Domenic AS. Baroreflex Activation in Drug-resistant Hypertension. US Cardiology 2009;29-32.

Doumas M, Douma S. Interventional management of resistant hypertension. Lancet 2009; 373(9671):1228-30.

Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep 2008;10:496-503.

Guido G, Giuseppe M. New therapeutic approaches for resistant hypertension. JNephrol 2012; 25(03): 276-81.

Ingrid JMS, Abraham AK, Jurg S, et al. Novel Baroreflex Activation Therapy in Resistant Hypertension. JACC 2010;56(15):1254-1258.

Jacob CJ, Omar B, Shivdev R, et al. Resistant Hypertension: A comprehensive Overview. J Hypertens 2013, 2:1.

Jennifer F, David S. Clinical approach in treatment of resistant hypertension. Integrated Blood Pressure Control 2009;1: 9-23.

Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens 2001;19:2271-2277.

Mahfoud F, Himmel F, Ukena C, et al. Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int 2011; 108:725-731.

Marvin M, John FS. Resistant or Difficult-to-Control Hypertension. N Engl J Med 2006;355:385-392.

Nikolaos S, Maria M. Interventional therapies for resistant hypertension. Hospital Chronicles 2012;7(1):128-135.

Pantelis AS, George LB. Resistant Hypertension: An Overview of Evaluation and Treatment. J. Am. Coll. Cardiol. 2008;52;1749-1757.

Pantelis AS. Epidemiology of Resistant Hypertension. The Journal of Clinical Hypertension July 2011; 13(7):523-28.

Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18(11):1422-1428.

Robert HF. Resistant hypertension. Heart 2012;98:254-261.

Roberto P, Mustafa IA, David AC. Characterization and Treatment of Resistant Hypertension. Curr Cardiol Rep. 2009 November; 11(6): 407-413.




DOI: https://doi.org/10.33476/jky.v23i2.116

Refbacks

  • There are currently no refbacks.


Copyright (c) 2015 Jurnal Kedokteran YARSI

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

__________________________________________________________________________________________

Copyright of YARSI Medical Journal.

Powered by OJS.

Creative Commons License

This work is licensed under a Creative Commons Attribution- NonCommercial 4.0 International License.